

GENOMERA[®] NOROVIRUS

-THE FASTEST MOLECULAR TEST

FOR DIRECT DETECTION AND
DIFFERENTIATION OF NOROVIRUS
GENOGROUPS I AND II



STOP NOROVIRUS WITH RAPID AND RELIABLE DIAGNOSIS - SAVING TIME AND MONEY



GENOMERA® NOROVIRUS BENEFITS

Simplicity

- Test is performed directly from stool without RNA extraction
- Very short and easy sample preparation
- All required materials are provided with the kit
- Reliable and automatically interpreted results



Saving money

- Very cost-efficient compared to other automated commercial molecular tests
- Fastest molecular test for GI and GII norovirus on the market
- Quick turn-around-time and suitability for single samples allows immediate action
- Avoiding unnecessary isolation

Streamlining laboratory workflow

- No need for resampling - liquid-based multipurpose eSwab™ sample collection enables sample transport and processing for further testing
- Possibility to prepare all samples at once and test during one work day
- Minimal amount of waste
- Low inhibition rate and high performance reduces need for re-analyses


Norovirus is estimated to cause almost 700 million illnesses worldwide and causing over \$60 billion societal costs each year¹. Even the most of the costs are due productivity losses, the norovirus infections can be lethal for children and elderly people.

Norovirus outbreaks can cause huge burden to hospitals and society. The appropriate isolation practise is key factor to prevent and control norovirus outbreaks.

As there are no preventive medicine or vaccination available, a quick and reliable diagnosis is a key factor in preventing spreading of the norovirus. Equally important is also to have a confirmation if acute gastroenteritis is not caused by norovirus.

RT-PCR is the only reliable method to detect norovirus, and nowadays RT-PCR is seen as a golden standard. Reliable and quick results will reduce the costs by improving patient management and isolation practises.


RELIABLE RESULTS WITH MINIMAL HANDS-ON-TIME



¹. Bartsch SM, et al. (2016). Global Economic Burden of Norovirus Gastroenteritis PLoS ONE 11(4):e0151219.

IMPROVING OUTBREAK MANAGEMENT WITH EXCELLENT CLINICAL PERFORMANCE

- **Negative predictive agreement 99.4%**
- **Positive predictive agreement 96.0%**
- Differentiation of GI and GII with comprehensive strain coverage
- Less than 80 minutes turn-around-time enables rapid clinical decision
- Scalable capacity 1-4 samples per run and on multi-instrument settings up to 32 samples per run



ORDERING INFORMATION

GenomEra Norovirus 20 tests	CDX-100-01-20
GenomEra Norovirus 40 tests	CDX-100-01-40
GenomEra CDX system	CDX-10-020

ABACUS Diagnostica

Abacus Diagnostica

Tykistökatu 4 D, Electrocity
FI-20520 Turku, FINLAND

Tel. +358 (0)20 7188 380
Fax +358 (0)20 7188 381

E-mail info@abacusdiagnostica.com
www.abacusdiagnostica.com

GenomEra® is a registered trademark of Abacus Diagnostica Oy

Norovirus v.2.0, Oct 2017